Formulary Monographs [EFAVIRENZ, 08180816]
|
|
EFAVIRENZ
|
|
|
|
|
|
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIB (NNRTI)
|
|
|
In combination with other antiretrovirals for the treatment of HIV-1
infection. Efavirenz usually is used in HIV nonnucleoside reverse transcriptase inhibitor-based (NNRTI-based) regimens that include efavirenz and 2 HIV nucleoside reverse transcriptase inhibitors (NRTIs) |
|
|
Psychiatric disorders, rash, increases in liver enzymes.
|
|
|
Adult: 600mg once daily on an empty stomach preferably at bedtime.
Pediatric: 3 years and older and weighing between 10-40kg: 200mg-600mg once daily . |
|
|
Efavirenz induces CYP3A and 2B6, and may alter plasma concentrations of drugs metabolized by these enzymes.
|
|
|
Efavirenz may cause fetal harm if administered during the first trimester of pregnancy.
|
|
|
The Centers for Disease Control and Prevention (CDC) and other experts recommend that HIV-infected women not breast-feed infants, regardless of antiretroviral therapy due to the risk of transmitting the virus through breastfeeding.
|
|
|
|